Australia markets closed

Celldex Therapeutics, Inc. (CLDX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
42.56+1.70 (+4.16%)
At close: 04:00PM EDT
42.50 -0.06 (-0.14%)
After hours: 06:33PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.69B
Enterprise value 2.27B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)287.61
Price/book (mrq)6.28
Enterprise value/revenue 330.10
Enterprise value/EBITDA -16.34

Trading information

Stock price history

Beta (5Y monthly) 1.56
52-week change 322.78%
S&P500 52-week change 322.43%
52-week high 353.18
52-week low 322.11
50-day moving average 342.04
200-day moving average 334.35

Share statistics

Avg vol (3-month) 3934.93k
Avg vol (10-day) 3580.78k
Shares outstanding 565.91M
Implied shares outstanding 665.91M
Float 852.81M
% held by insiders 10.34%
% held by institutions 196.25%
Shares short (15 Apr 2024) 46.75M
Short ratio (15 Apr 2024) 48.62
Short % of float (15 Apr 2024) 411.86%
Short % of shares outstanding (15 Apr 2024) 410.24%
Shares short (prior month 15 Mar 2024) 45.9M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 311 Feb 2019
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 311 Feb 2019

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-850.33%

Management effectiveness

Return on assets (ttm)-21.70%
Return on equity (ttm)-37.45%

Income statement

Revenue (ttm)6.88M
Revenue per share (ttm)0.14
Quarterly revenue growth (yoy)156.10%
Gross profit (ttm)N/A
EBITDA -139.03M
Net income avi to common (ttm)-141.43M
Diluted EPS (ttm)-2.92
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)423.6M
Total cash per share (mrq)7.58
Total debt (mrq)2.54M
Total debt/equity (mrq)0.59%
Current ratio (mrq)13.87
Book value per share (mrq)7.68

Cash flow statement

Operating cash flow (ttm)-107.29M
Levered free cash flow (ttm)-46.7M